Acumen Pharmaceuticals (ABOS) Preferred Stock Liabilities (2020 - 2021)
Acumen Pharmaceuticals (ABOS) posted Preferred Stock Liabilities of $174.5 million for Q2 2021, up 208.02% sequentially from $56.7 million in Q4 2020.
Acumen Pharmaceuticals (ABOS) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Acumen Pharmaceuticals has reported Preferred Stock Liabilities for 2 years, with the latest figure at $174.5 million in Q2 2021.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $174.5 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $174.5 million (changed N/A YoY) and the FY2020 annual result came in at $56.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $174.5 million in Q2 2021 per ABOS's latest filing, from $56.7 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $174.5 million in Q2 2021 and troughed at $56.7 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 174.50 Mn |
| Dec 31, 2020 | 56.65 Mn |